American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Novo Nordisk stock just tanked 25%: here’s what happened

by admin December 21, 2024
December 21, 2024
Novo Nordisk stock just tanked 25%: here’s what happened

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema.

The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.7% in a late-stage trial – lower than 25% it had originally expected.

Novo Nordisk stock was down nearly 25% at one point on Friday. Its anti-obesity rival, Eli Lilly & Co, in comparison, jumped as much as 8.0% in premarket.

Others that are positioned to compete with Novo Nordisk in the weight loss market include Amgen, Zealand Pharma, and more recently, Merck & Co Inc.

Why does CagriSema news matter for Novo Nordisk stock

The announcement is significant for Novo Nordisk stock as the management expected CagriSema to emerge as the next-generation treatment for obesity.

CagriSema is a two-drug injectable that combines Cagrilintide and Semaglutide.

Cagrilintide is a novel approach for weight loss but Semaglutide is the active ingredient of the company’s Wegovy as well.

The 68-week phase three trial involving CagriSema saw participation from 3,400 people who were suffering from obesity or were otherwise overweight, as per the press release the European drugmaker published on Friday.

Note that Novo Nordisk is scheduled to share the outcome of a phase three trial that’s testing CagriSema in obese/overweight adults with type 2 diabetes in the coming year as well.

Novo Nordisk stock is now down more than 45% versus its high in late June.

CagriSema outperformed Wegovy in weight loss

On the plus side, the new weight-loss treatment was “on part with best-in-class treatments.”

That’s because CagriSema delivered better results in terms of helping people lower their body weights than Wegovy in the late-stage trial.

“CagriSema demonstrated superiority over both Semaglutide and Cagrilintide in monotherapy in REDEFINE 1 trial. This was achieved even though only 57% of patients reached the highest dose,” Martin Holse Lanage – an executive vice president of Novo Nordisk said in a press release today.

Still, Novo Nordisk stock tanked sharply this morning as investors focused more on the fact that CagriSema failed to meet the company’s original expectations in the phase three trial.

Novo Nordisk is not bailing on CagriSema

Novo Nordisk will continue to “further explore the additional weight-loss potential of CagriSema” and expects to seek regulatory approval for the treatment by the end of 2025.

Shares of the pharmaceutical giant are still slipping at writing perhaps because it wasn’t the first setback for Novo Nordisk this month.  

Earlier in December, a Lilly sponsored trial that drew head-to-head comparison between its Zepbound and Novo Nordisk’s Wegovy established the former’s superiority as an anti-obesity treatment.

Zepbound enabled patients lower their body weights by more than 20% in that trial over 72 weeks versus a significantly lower 13.7% reduction in weight observed for Wegovy.

Novo Nordisk shares do not currently pay a dividend to appear any more attractive for the income investors either.

The post Novo Nordisk stock just tanked 25%: here’s what happened appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Humacyte stock may fail to sustain today’s gains: find out more
next post
Short US30: bearish breakdown below key trendline, eyeing further downside amid economic uncertainty

Related Posts

Europe markets open: Stoxx 600 rallies over 1%...

May 12, 2025

Higher tax filing costs could take a bite...

February 3, 2024

Li Auto stock: Tesla and Nio rival could...

September 25, 2024

Fed chair Jerome Powell: No sign of stagflation...

May 3, 2024

Procter & Gamble to cut 7,000 jobs as...

June 5, 2025

Asian shares display mixed performance amidst trade tensions...

February 12, 2025

Short SMCI: Struggling to break $48.5 resistance, bearish...

October 26, 2024

Flipkart injects $30M into Supermoney to expand lending...

September 23, 2025

Abortion bans drive away up to half of...

May 9, 2024

Abu Dhabi launches first Nvidia AI tech center...

September 22, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Bulgaria plans for continuous oil supply for Lukoil-owned refinery after US sanctions

      October 26, 2025
    • Apple Q4 earnings preview: here’s what to expect

      October 26, 2025
    • France’s offshore wind ambitions stalled by political turmoil

      October 26, 2025
    • Europe bulletin: Zelensky calls for more weapons, Russia warns against EU sanctions

      October 26, 2025
    • US digest: Jeffries endorses Mamdani, Ford’s stock surge, US sanctions Colombian president

      October 26, 2025

    Categories

    • Business (4,373)
    • Investing (3,014)
    • Latest News (2,103)
    • Politics (1,541)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved